Skip to content

Author

Xuejiao Hu

We have 1 of 5 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Virtual screening and MD simulation-guided discovery of CDK12-IN-3, a potent ALK inhibitor suppressing neuroblastoma growth in vitro and in vivo

CDK12-IN-3 is validated as a novel selective ALK inhibitor with potent anti-NB activity, providing a promising lead compound and an efficient dynamic simulation-guided drug repurposing paradigm for overcoming ALK inhibitor resistance in high-risk NB.

Tianyi Liu, Xuejiao Hu, Wenxin Yan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.